

May 30, 2022

To

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
Tel: 022 - 2272 1233 /4  
Fax: 022 - 22721919

Ref: Aragen Life Sciences Private Limited

Scrip Code: 973783


ISIN: INE483I07010

**Sub: Publication of Extract of Financial Results in an English national daily newspaper**

In compliance with Regulation 52 (8) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has, on Saturday, 28<sup>th</sup> May, 2022, published in The Economic Times, an English national daily newspaper, an extract of its Financial Results for the quarter and the year ended 31<sup>st</sup> March, 2022, which were approved by its Board of Directors and disseminated on Thursday, the 26<sup>th</sup> May, 2022 to the stock exchange BSE Limited, where the debt securities of the Company are listed. A copy of the newspaper cutting is enclosed herewith.

Please take on your records.

**For Aragen Life Sciences Private Limited**



**Ramakrishna Kasturi**  
Company Secretary & Compliance Officer



## ARAGEN LIFE SCIENCES PRIVATE LIMITED

(formerly known as GVK Biosciences Private Limited)

CIN: U74999TG2000PTC035826

Registered and Corporate Office: Plot 28A, IDA Nacharam, Hyderabad  
Telangana-500076, India

Tel: +91 40 6692 9999 F: +91 40 6692 9900

Email id: compliances@aragen.com, website:www.aragen.com

Extract of financial results for the quarter and year ended 31 March 2022

(₹ in million)

S. No.	Particulars	Standalone			Consolidated		
		Quarter ended	For the year ended		Quarter ended	For the year ended	
		31 March 2022	31 March 2022	31 March 2021	31 March 2022	31 March 2022	31 March 2021
		Unaudited	Audited	Audited	Unaudited	Audited	Audited
1	Total Income from operations	3,181.98	12,359.68	9,501.77	3,654.16	13,873.61	11,333.85
2	Net Profit / (Loss) for the period before tax, exceptional and/or extraordinary items)	665.72	2,776.38	1,865.95	651.36	2,676.49	2,174.68
3	Net Profit / (Loss) for the period before tax (after exceptional and/or extraordinary items)	665.72	2,776.38	1,865.95	651.36	2,676.49	2,174.68
4	Net Profit / (Loss) for the period after tax (after exceptional and/or extraordinary items)	517.37	2,112.66	1,380.39	501.06	1,977.51	1,678.82
5	Total Comprehensive Income for the period	468.03	2,123.06	1,713.18	441.74	1,971.63	2,002.31
6	Paid up Equity Share Capital	681.38	681.38	669.82	681.38	681.38	669.82
7	Reserves (excluding Revaluation Reserve)	9,728.67	9,728.67	7,382.59	9,620.69	9,620.69	7,438.03
8	Securities Premium Account	391.33	391.33	185.81	391.33	391.33	185.81
9	Net worth	10,410.05	10,410.05	8,052.41	10,302.07	10,302.07	8,107.85
10	Paid up Debt Capital/ Outstanding Debt	5,175.72	5,175.72	2,459.89	5,175.72	5,175.72	2,459.89
11	Debt Equity Ratio	0.50	0.50	0.31	0.50	0.50	0.30
12	Earnings Per Share (EPS)*						
	Basic EPS (Rs)	7.70	31.46	20.86	7.35	29.24	25.37
	Diluted EPS (Rs)	7.62	31.11	20.35	7.26	28.91	24.75
13	Debenture Redemption Reserve	200.00	200.00	-	200.00	200.00	-
14	Capital Redemption Reserve	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
15	Outstanding redeemable preference shares	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.
16	Debt Service Coverage Ratio*	1.87	3.36	4.71	1.87	3.28	3.91
17	Interest Service Coverage Ratio*	7.75	13.25	11.93	7.48	12.43	13.01

\* for the quarter, ratios are not annualised

## Notes:

- The above is an extract of the detailed format of quarterly/annual financial results filed with the stock exchange under Regulation 52 of the Listing Regulations as the company's debt securities are listed. The full format of the quarterly/annual financial results are available on the websites of the stock exchange- BSE Limited at www.bseindia.com and the company at www.aragen.com.
- For the other line items referred to in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at www.bseindia.com.
- Figures for the quarter ended 31 March 2022 represents the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the third quarter of the current financial year.
- The Company started publishing quarterly results from quarter ended 31 March 2022 and hence quarterly figures for the quarter ended 31 March 2021 have not been given basis exemption allowed by SEBI vide their circular dated 05 October 2021.

For Aragen Life Sciences Private Limited  
Sd/-Manmahesh Kantipudi  
Director & CEO  
DIN: 05241166Date: 26<sup>th</sup> May, 2022  
Place: Hyderabad